[ad_1]
One study reported that canagliflozin, a diabetes medicine, significantly reduced the risk of kidney failure and cardiovascular problems in type 2 diabetes.
Canagliflozin is an inhibitor of SGLT2, marketed under the name of Invokana, which allows the kidneys to lower the level of glucose in the blood, as excess glucose in the blood is removed from the body by l & # 39; urine.
In this new international study, the drug reduced the risk of end-stage renal disease by 32%. It also reduced by 34% the likelihood of kidney (renal) mortality, as well as 22 emergency hospitalizations in heart failure and 25 events of cardiovascular death, heart attack or stroke by less.
The study involved 4,401 people with type 2 diabetes and chronic kidney disease from 34 countries. They were divided into two groups, one receiving the drug and the other, the placebo, and were followed three times between March 2014 and May 2017.
The drug has already been found to have a higher risk of lower limb amputation, but this new research suggests that there is no increased risk. In addition, bone fracture rates were the same between the two groups.
However, the risk of diabetic ketoacidosis (DKA), a dangerous short-term complication of diabetes that can be fatal without urgent treatment, was higher in participants taking canagliflozin.
The limitations of the study included not studying people with advanced renal failure, or those with kidney problems unrelated to type 2 diabetes.
The research was published in the New England Journal of Medicine.
[ad_2]
Source link
